Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 1

Conditions

Colorectal Neoplasms 4Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Fever 1Febrile Neutropenia 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rectal Neoplasms × pegfilgrastim × Gastrointestinal × Clear all
NCT00094809 2018-10-17

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Amgen

Phase 2 Completed
252 enrolled 19 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡